Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
AIDS Care ; 35(12): 1836-1843, 2023 12.
Artículo en Inglés | MEDLINE | ID: mdl-36259779

RESUMEN

This study assessed predictors of stable HIV viral suppression in a racially diverse sample of persons living with HIV (PWH) in the southern US. A total of 700 PWH were recruited from one of four HIV clinics in Metro Atlanta, GA. Data were collected from September 2012 to July 2017, and HIV viral loads were retrieved from EMR for 18 months. The baseline visits and EMR data were used for current analyses. Durable viral suppression was categorized as 1. Remain suppressed, 2. Remain unsuppressed, and 3. Unstable suppression. The number of antiretroviral medications and age were significantly associated with durable viral suppression. Older age, fewer ART medications and availability of social support were positively associated with durable viral suppression over the 18-month observation period. Findings suggest that regimen complexity is potentially a better predictor of viral suppression than self-reported medication adherence. The need for consensus on the definition of durable viral suppression is also urged.


Asunto(s)
Fármacos Anti-VIH , Infecciones por VIH , Humanos , Infecciones por VIH/tratamiento farmacológico , Antirretrovirales/uso terapéutico , Carga Viral , Cumplimiento de la Medicación , Fármacos Anti-VIH/uso terapéutico
2.
Artículo en Inglés | MEDLINE | ID: mdl-36711436

RESUMEN

Context: There are research-grade devices that have been validated to measure either heart rate (HR) by electrocardiography (ECG) with a Polar chest strap, or step count with ACTiGraph accelerometer. However, wearable activity trackers that measure HR and steps concurrently have been tested against research-grade accelerometers and HR monitors with conflicting results. This review examines validation studies of the Fitbit Charge 2 (FBC2) for accuracy in measuring HR and step count and evaluates the device's reliability for use by researchers and clinicians. Design: This registered review was conducted using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The robvis (risk-of-bias visualization) tool was used to assess the strength of each considered article. Eligibility Criteria: Eligible articles published between 2018 and 2019 were identified using PubMed, CINHAL, Embase, Cochran, and World of Science databases and hand-searches. All articles were HR and/or step count validation studies for the FBC2 in adult ambulatory populations. Study Selection: Eight articles were examined in accordance with the eligibility criteria alignment and agreement among the authors and research librarian. Main Outcome Measures: Concordance correlation coefficients (CCC) were used to measure agreement between the tracker and criterion devices. Mean absolute percent error (MAPE) was used to average the individual absolute percent errors. Results: Studies that measured CCC found agreement between the FBC2 and criterion devices ranged between 26% and 92% for HR monitoring, decreasing in accuracy as exercise intensity increased. Inversely, CCC increased from 38% to 99% for step count when exercise intensity increased. HR error between MAPE was 9.21% to 68% and showed more error as exercise intensity increased. Step measurement error MAPE was 12% for healthy persons aged 24-72 years but was reported at 46% in an older population with heart failure. Conclusions: Relative agreement with criterion and low-to-moderate MAPE were consistent in most studies reviewed and support validation of the FBC2 to accurately measure HR at low or moderate exercise intensities. However, more investigation controlling testing and measurement congruency is needed to validate step capabilities. The literature supports the validity of the FBC2 to accurately monitor HR, but for step count is inconclusive so the device may not be suitable for recommended use in all populations.

3.
J Assoc Nurses AIDS Care ; 32(3): 306-321, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-33449578

RESUMEN

ABSTRACT: Neurocognitive problems have been endemic to the HIV epidemic since its beginning. Four decades later, these problems persist, but currently, they are attributed to HIV-induced inflammation, the long-term effects of combination antiretroviral therapy, lifestyle (i.e., physical activity, drug use), psychiatric, and age-associated comorbidities (i.e., heart disease, hypertension). In many cases, persons living with HIV (PLWH) may develop cognitive problems as a function of accelerated or accentuated normal aging and lifestyle rather than HIV itself. Nonetheless, such cognitive impairments can interfere with HIV care, including medication adherence and attending clinic appointments. With more than half of PLWH 50 years and older, and 30%-50% of all PLWH meeting the criteria for HIV-associated neurocognitive disorder, those aging with HIV may be more vulnerable to developing cognitive problems. This state of the science article provides an overview of current issues and provides implications for practice, policy, and research to promote successful cognitive functioning in PLWH.


Asunto(s)
Envejecimiento , Disfunción Cognitiva/complicaciones , Disfunción Cognitiva/virología , Reserva Cognitiva/fisiología , Infecciones por VIH/psicología , Trastornos Neurocognitivos/complicaciones , Anciano , Terapia Antirretroviral Altamente Activa , Cognición/fisiología , Disfunción Cognitiva/psicología , Femenino , Infecciones por VIH/complicaciones , Infecciones por VIH/tratamiento farmacológico , Humanos , Masculino , Persona de Mediana Edad , Plasticidad Neuronal , Pruebas Neuropsicológicas , Trastornos Relacionados con Sustancias
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...